Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Bruera, Gemma ^a   Cannita, Katia ^a   Di Giacomo, Daniela ^b   Lamy, Aude ^c   Troncone, Giancarlo ^d   Dal Mas, Antonella ^e   Coletti, Gino ^e   Frébourg, Thierry ^f   Sabourin, Jean C ^c   Tosi, Mario ^f   Ficorella, Corrado ^a   Ricevuto, Enrico ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f UNIVERSITÉ DE ROUEN   (France)

Author keywords

Disease Extension; Intensive Regimen; KRAS mutations; Metastatic Colorectal Cancer; Triplet Chemotherapy Plus Bevacizumab

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CODON; COLORECTAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84868501969     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-135     Document Type: Article

References (37)

1. Bruera G, Ricevuto E. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52. Exp Opin Biol Ther 2011, 11:821-824.
2. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Pugliesi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011, 103:21-30. 10.1093/jnci/djq456, 21123833.
3. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:845-852. 10.1016/S1470-2045(10)70175-3, 20702138.
4. Bruera G, Santomaggio A, Cannita K, Lanfiuti Baldi P, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010, 10:67. 10.1186/1471-2407-10-67, 2846883, 20181281.
5. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadiuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010, 103:1542-1547. 10.1038/sj.bjc.6605940, 2990583, 20959822.
6. Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer 2012, 11:119-126. 10.1016/j.clcc.2011.11.002, 22206922.
7. Yarden Y, Sliwkowsky MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
8. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272. 10.1158/1078-0432.CCR-05-1554, 17000658.
9. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279. 10.1016/j.advenzreg.2006.01.004, 16854453.
10. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR. Cosmic 2005. Br J Cancer 2006, 94:318-322. 10.1038/sj.bjc.6602928, 2361125, 16421597.
11. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
12. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young Y, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JWC, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-696. 10.1054/bjoc.2001.1964, 2364126, 11531254.
13. Normanno N, Tejpar S, Morbillo F, De Luca A, Van Cutsem E, Ciardiello F. Implication of KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Onc 2009, 6:519-527.
14. Schubbert S, Shannon K, Bollag G. Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308. 10.1038/nrc2109, 17384584.
15. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
16. Zauber P, Sabbath-Solitare M, Marotta SP, Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchorous metastases compared with the findings in accompanying adenomas. Mol Pathol 2003, 56:137-140. 10.1136/mp.56.3.137, 1187308, 12782759.
17. Artale S, Sartore-Bianchi A, Veronese S, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008, 26:4217-4219. 10.1200/JCO.2008.18.7286, 18757341.
18. Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008, 14:4830-4835. 10.1158/1078-0432.CCR-07-4906, 18676755.
19. Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, Colomba P, Tagliavia M, La Farina M. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of K-ras and p53 mutations. Biochem Biophys Res Commun 2004, 325:784-791. 10.1016/j.bbrc.2004.10.111, 15541358.
20. Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991, 49:875-879. 10.1002/ijc.2910490613, 1959991.
21. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
22. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 351:1408-1417.
23. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucoverin, and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671. 10.1200/JCO.2008.20.8397, 19114683.
24. Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P. Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: a dose-finding study. Oncol Rep 2006, 15:1345-1350.
25. Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti Baldi P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C, on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia) Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep 2010, 23:1635-40. on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio-Oncologia).
26. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboué R, Tuech JJ, Queniet AM, Paillot B, Sabouirin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169. 10.1038/sj.bjc.6603685, 2360149, 17375050.
27. Lamy A, Blanchard F, Le Pessot F, Sesboué R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 2011, 24:1090-1100. 10.1038/modpathol.2011.60, 21516079.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
29. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958, 53:457-481.
30. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 1972, 135:185-206.
31. Hecht JR, Mitchell E, Chidiac T, scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680. 10.1200/JCO.2008.19.8135, 19114685.
32. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JHJM, Dalesio O, Punt CJA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572. 10.1056/NEJMoa0808268, 19196673.
33. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocàkova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of Panitumumab with infusional fluorouracil, leicovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME trial. J Clin Oncol 2010, 28:4697-4705. 10.1200/JCO.2009.27.4860, 20921465.
34. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546. 10.1093/annonc/mdq632, 21228335.
35. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989. 10.1093/jnci/dji174, 15998951.
36. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with Cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 2010, 11:38-47. 10.1016/S1470-2045(09)70330-4, 19942479.
37. Guerrero S, Casanova I, Farrè L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000, 60:6750-6756.